Related Experiment Videos
Reoperation on stentless aortic xenografts
G B Luciani1, P Bertolini, B Vecchi
1Division of Cardiac Surgery, University of Verona, Italy. gbluciani@yahoo.com
The Annals of Thoracic Surgery
|February 4, 1999
Summary
Reoperation for stentless aortic xenograft valve failure is rare, with most cases occurring early. The O'Brien-Angell valve showed a higher reintervention rate, but reoperation is generally safe and effective.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Prosthetic Valve Research
Background:
- Stentless xenografts are used for aortic valve replacement.
- Previous valve failure requiring reoperation was infrequent.
- This study aimed to determine the prevalence and outcomes of reoperation for stentless aortic xenograft valves.
Purpose of the Study:
- To establish the prevalence of reoperation for stentless aortic xenograft valves.
- To evaluate the outcomes of patients requiring reoperation.
- To compare reoperation rates among different stentless xenograft models.
Main Methods:
- A review of 199 patients who underwent stentless aortic valve replacement between October 1992 and October 1996.
- Analysis of three types of stentless prostheses: Biocor PSB, Toronto SPV, and O'Brien-Angell.
- Follow-up for up to 4 years to assess reoperation rates and causes.
Main Results:
- Overall reoperation rate was 3.5% (7 patients), with 3% (6 patients) being valve-related.
- Most valve-related reoperations occurred early (<12 months post-implant).
- The O'Brien-Angell valve had a significantly higher reoperation rate (12%) compared to Biocor PSB (1%) and Toronto SPV (0%) (p=0.0039).
Conclusions:
- Reoperation for stentless xenograft failure is uncommon.
- The O'Brien-Angell valve may have a higher risk of early reintervention due to non-structural failure.
- Reoperation for stentless xenograft failure is typically a straightforward procedure with low surgical risk.